ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.
ViAqua Therapeutics has raised $8.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2023.
ViAqua Therapeutics's investors include S2G Investments, Israel Innovation Authority, Clay Capital, Technion - Israel Institute of Technology, Rabo Ventures.
ViAqua Therapeutics is headquartered in Misgav, Israel.
ViAqua Therapeutics is developing the first orally administered treatment for aquaculture.
ViAqua Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ViAqua Therapeutics — Funding & Investors." VCBacked, September 5, 2023, https://www.vcbacked.co/company/viaqua-therapeutics. Accessed August 8, 2026.
VCBacked. (2023). ViAqua Therapeutics — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/viaqua-therapeutics
{{cite web |title=ViAqua Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/viaqua-therapeutics |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated